- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07:22 | Stonebridge Capital Gains from Caris Nasdaq Listing | 1 | BusinessKorea | ||
| Mi | Caris Life Sciences trades higher on market debut | 6 | Seeking Alpha | ||
| Mi | Sixth Street-backed Caris Life valued at $7.66 billion in strong Nasdaq debut | 1 | Reuters | ||
| Mi | Caris Life Sciences Opens at $27, IPO Priced at $21 | 1 | Investing.com | ||
| Mi | Caris Life Sciences shares jump 29% in Nasdaq debut | 2 | Investing.com | ||
| Mi | Caris Life Sciences prices IPO at $21, above the upwardly revised range | 2 | Renaissance Capital | ||
| Mi | Caris Life Sciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| CARIS LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| Mi | Cancer diagnostics firm Caris prices IPO at $21 per share | 1 | Seeking Alpha | ||
| Mi | Caris Life Sciences Prices IPO Of About 23.53 Mln Shares At $21.00/shr | 482 | AFX News | WASHINGTON (dpa-AFX) - Caris Life Sciences (Caris) announced that it has priced its initial public offering of about 23.53 million shares of its common stock at a public offering price of $21.00... ► Artikel lesen | |
| Di | Sixth Street-backed Caris ups IPO range, targeting $5.7bn valuation | 1 | Private Equity Wire | ||
| Di | Caris swells its planned IPO, seeking $5.7bn valuation | 1 | pharmaphorum | ||
| Mo | Caris Life Sciences raises IPO price range for Nasdaq listing | 1 | Seeking Alpha | ||
| Mo | Oncology precision medicine platform Caris Life Sciences raises range to $19 to $20 ahead of $459 million IPO | 1 | Renaissance Capital | ||
| Mo | Caris Life Sciences Raises Price Range of 23.53M Share IPO at $19-$20/sh | 5 | Investing.com | ||
| Mo | U.S. cancer diagnostic firm Caris raises IPO price range | 1 | Investing.com | ||
| Mo | Caris Life Sciences, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| Fr | Caris Life Sciences, Inc. - 8-A12B, Registration of securities | 1 | SEC Filings | ||
| 11.06. | Sixth Street-backed Caris Life Sciences eyes $5.3bn valuation ahead of IPO | 1 | Private Equity Wire | ||
| 09.06. | Caris Life Sciences plans to raise about 424M in IPO | 2 | Seeking Alpha | ||
| 09.06. | Oncology precision medicine platform Caris Life Sciences sets terms for $400 million IPO | 2 | Renaissance Capital |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,575 | 0,00 % | Verhaltene Kauflaune bei Aktie von Qiagen NV (40,695 €) | Die Wertschätzung für den Anteilsschein von Qiagen NV hat sich am Aktienmarkt heute kaum geändert. Der jüngste Kurs betrug 40,70 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei dem... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 46,790 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
| EVOTEC | 6,850 | 0,00 % | Nächste Übernahme und bahnbrechende Forschung - BioNTech, CureVac, Evotec, Vidac Pharma | Am Mittwoch konnten die Chefunterhändler von China und der USA bei ihren Verhandlungen in London Vollzug melden. Die dort getroffenen Vereinbarungen werden von den jeweiligen Staatschef Xi Jinping und... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 2,570 | +0,78 % | Cantor Fitzgerald behält Kursziel von 13 US-Dollar für Taysha Gene Therapies bei | ||
| VERVE THERAPEUTICS | 11,130 | 0,00 % | Eli Lilly will Verve Therapeutics schlucken - 113 Prozent Aufschlag! | Der Pharma-Riese Eli Lilly bleibt seiner aktiven M&A-Strategie treu. Die Amerikaner wollen sich mit der Übernahme von Verve Therapeutics im Gene-Editing-Bereich verstärken. Eli Lilly lässt sich den... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,095 | 0,00 % | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| REGENCELL BIOSCIENCE | 63,35 | 0,00 % | Regencell Bioscience Holdings Ltd - 6-K, Report of foreign issuer | ||
| IMMUNOME | 8,830 | 0,00 % | Immunome Inc. - 8-K, Current Report | ||
| LEXEO THERAPEUTICS | 4,240 | 0,00 % | Lexeo Therapeutics files to sell 41.63M shares of common stock for holders | ||
| ADMA BIOLOGICS | 18,135 | 0,00 % | ADMA Looks to Expand Asceniv's Label: Will This Boost Sales? | ||
| NURIX THERAPEUTICS | 11,620 | +2,02 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 13,660 | 0,00 % | Arcutis Biotherapeutics, Inc. - 8-K, Current Report | ||
| DYNE THERAPEUTICS | 10,790 | 0,00 % | Dyne Therapeutics Submits Revised ACHIEVE Trial Protocol To FDA Elevating VHOT To Primary Endpoint | WASHINGTON (dpa-AFX) - Dyne Therapeutics (DYN) announced the FDA has granted Breakthrough Therapy Designation to DYNE-101 for the treatment of myotonic dystrophy type 1. The company also announced... ► Artikel lesen | |
| TANGO THERAPEUTICS | 4,800 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors | BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 12,350 | 0,00 % | EU Grants Marketing Authorization For KOSTAIVE To CSL And Arcturus Therapeutics | CANBERA (dpa-AFX) - Biotechnology firm CSL Ltd. (CSL.AX, CMXHF.PK) and sa-mRNA pioneer Arcturus Therapeutics Ltd. (ARCT) announced Friday that the European Commission has granted marketing authorization... ► Artikel lesen |
Das Unternehmen CARIS LIFE SCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 27,830 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CARIS LIFE SCIENCES INC finden Sie auf Wallstreet Online.